Principal Financial Group
FULC icon

Principal Financial Group’s Fulcrum Therapeutics FULC Stock Holding History

Principal Financial Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-97,688
Closed -$1.1M – 2225
2025
Q4 		$1.1M Buy
97,688
+31,138
+47% +$317K ﹤0.01% 1943
2025
Q3 		$612K Buy
+66,550
New +$482K ﹤0.01% 2016
2024
Q2 		– Sell
-16,233
Closed -$153K – 2402
2024
Q1 		$153K Sell
16,233
-1,760
-10% -$15.7K ﹤0.01% 2217
2023
Q4 		$121K Sell
17,993
-756
-4% -$3.35K ﹤0.01% 2241
2023
Q3 		$83.2K Buy
18,749
+1,687
+10% +$7.37K ﹤0.01% 2307
2023
Q2 		$56.3K Buy
17,062
+1,770
+12% +$5.2K ﹤0.01% 2349
2023
Q1 		$43.6K Buy
15,292
+2,471
+19% +$22.1K ﹤0.01% 2384
2022
Q4 		$93.3K Buy
+12,821
New +$83.6K ﹤0.01% 2302

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Principal Financial Group's FULC Position: Q1 2026 in Review

Principal Financial Group sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 97,688 shares — an estimated $1.1M sold.

Principal Financial Group first reported a position in FULC in Q4 2022 and held it in 8 quarters. The position peaked at $1.1M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Principal Financial Group reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Principal Financial Group sold 97,688 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.1M.
  • Principal Financial Group first reported a position in Fulcrum Therapeutics in Q4 2022 and held it in 8 quarters.
  • Principal Financial Group's Fulcrum Therapeutics position peaked at $1.1M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.